Profiel
Richard W.
Krawiec worked as VP-Investor Relations & Corporate Affairs at Amylin Pharmaceuticals, La Jolla Pharmaceutical Co., and IDEC Pharmaceuticals Corp.
He also worked as VP-Investor Relations & Corporate Communications at Jazz Pharmaceuticals (EUSA Pharma USA), Inc. He was VP-Corporate Affairs & Head-Investor Relations at Progenics Pharmaceuticals, Inc. Dr. Krawiec received an undergraduate degree from Boston University and a doctorate degree from the University of Rhode Island.
Eerdere bekende functies van Richard W. Krawiec
| Bedrijven | Functie | Einde |
|---|---|---|
| PROGENICS PHARMACEUTICALS, INC. | Public Communications Contact | 01-12-2009 |
Jazz Pharmaceuticals (EUSA Pharma USA), Inc.
 Jazz Pharmaceuticals (EUSA Pharma USA), Inc. BiotechnologyHealth Technology Jazz Pharmaceuticals (EUSA Pharma USA), Inc. develops and markets biopharmaceutical products. The company was founded on November 7, 1980 and is headquartered in Princeton, NJ. | Public Communications Contact | 01-01-2001 |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Public Communications Contact | - |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Public Communications Contact | - |
| LA JOLLA PHARMACEUTICAL COMPANY | Public Communications Contact | - |
Opleiding van Richard W. Krawiec
| Boston University | Undergraduate Degree |
| University of Rhode Island | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
Jazz Pharmaceuticals (EUSA Pharma USA), Inc.
Jazz Pharmaceuticals (EUSA Pharma USA), Inc. BiotechnologyHealth Technology Jazz Pharmaceuticals (EUSA Pharma USA), Inc. develops and markets biopharmaceutical products. The company was founded on November 7, 1980 and is headquartered in Princeton, NJ. | Health Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
